Key facts
- NovaSight’s last known valuation is $47.3M (Aug 2025).
- It has raised $38.3M; the latest was Later Stage VC ($7.9M) in Aug 2025.
- Notable investors include Innovation Authority, Yunjin (Suzhou) Capital Management, Arbelon Holdings, Club 100 plus, Dagesh — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for NovaSight
- ·The full record, as it builds
Funding rounds
No funding rounds for NovaSight are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About NovaSight
Developer of a pediatric ophthalmology medical device intended to integrate data analytics into a range of medical devices. The company aims to prevent vision impairments among pediatric patients using eye-tracking-based technology in novel diagnostic, therapeutic, and preventive solutions that are designed for the unique needs and attention span of children, enabling patients to receive the right eye care devices required.
- Sector
- Healthcare
- HQ
- Lod, Israel
- Founded
- 2016
- Employees
- 14
- Website
- nova-sight.com/
- Ownership
- Privately Held (backing)
NovaSight doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NovaSight shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NovaSight in its N-PORT filings yet. We sweep new filings monthly.